CJC-1295 with DAC (Drug Affinity Complex) — long-acting growth hormone releasing hormone analog. Sourced from China. Purity tested per batch.
CJC-1295 With DAC is a research compound available through our china peptide catalog as a finished, lyophilized vial from an established Chinese manufacturer. It belongs to the GHRH analogue with Drug Affinity Complex (albumin-binding)
Research Areas
GH axis pharmacology, sustained GHRH receptor stimulation, IGF-1 regulation, pituitary function
Available Variants
| Name | Strength | Pack Size | Purity | Availability |
|---|---|---|---|---|
| CJC-1295 With DAC | 2 mg | 10 vials | ≥98% | In Stock |
| CJC-1295 With DAC | 5 mg | 10 vials | ≥98% | Out of Stock |
Specification Highlights
Quality & Testing
Testing method: HPLC / LC-MS . Products are supplied against the specification shown on the applicable product page. The standard catalog purity specification is ≥98% unless otherwise stated. Product-specific specifications and quality-control information may vary by compound and batch. Every batch is tested by the manufacturer for purity and concentration as part of routine quality control, using methods such as HPLC and LC-MS. These results are kept in the manufacturer’s internal quality-control records and are not issued as a separate certificate or document.
Research Areas
Sustained GHRH Receptor Pharmacology CJC-1295 with DAC enables sustained GHRHR activation over days rather than minutes, producing a distinct pharmacodynamic profile compared to short-acting GHRH analogues. Research has examined how prolonged GHRHR occupancy affects GH pulse architecture, IGF-1 accumulation, and pituitary somatotroph behavior. This sustained profile is used as an experimental counterpoint to pulsatile GH secretion models in GH axis biology. Drug Affinity Complex Technology Research The DAC modification — maleimido-propionyl-lysine enabling covalent albumin binding — is itself a pharmacokinetic research tool. Studies examining DAC-modified compounds have contributed to understanding of albumin-binding half-life extension strategies, reaction kinetics of maleimide-thiol conjugation in vivo, and the pharmacokinetic implications of albumin as a drug carrier. CJC-1295 with DAC is a well-characterized model compound in this field. GH/IGF-1 Axis Modulation Studies Research protocols using CJC-1295 with DAC have examined downstream GH axis effects including IGF-1 elevation, GH-responsive tissue changes in rodent models, and pituitary feedback regulation. Its use in combination with GHRPs (GHRP-2, GHRP-6, ipamorelin) allows researchers to study synergistic GHRHR and GHS-R1a co-stimulation under conditions of prolonged versus acute GHRH receptor engagement. ## Sourcing CJC-1295 With DAC From China
CJC-1295 With DAC is available through our platform as a china peptide sourced directly from an established Chinese manufacturer. Three points define how we handle it:
- Factory-direct, not trader-sourced. We confirm availability and specification with the manufacturer before the order is confirmed. There is no intermediary resale of unknown-origin vials in this catalog.
- Specification before shipment. The purity and concentration specification shown on this page is the manufacturer’s batch specification. Product-specific quality-control information travels with the order.
- Research-use discipline. Like every listing in our catalog, CJC-1295 With DAC is supplied for laboratory research use only, under strict research-use terms.
For buyers comparing chinese peptides suppliers, the practical test is whether the seller can name the manufacturer and show the batch documentation. We work the other way around: the manufacturer and the documentation are the offer. Browse the full catalog or see how sourcing works.
Available Variants
| Name | Strength | Pack Size | Purity | Availability |
|---|---|---|---|---|
| CJC-1295 With DAC | 2 mg | 10 vials | ≥98% | In Stock |
| CJC-1295 With DAC | 5 mg | 10 vials | ≥98% | Out of Stock |
Specification Highlights
Quality & Testing
Testing method: HPLC / LC-MS . Products are supplied against the specification shown on the applicable product page. The standard catalog purity specification is ≥98% unless otherwise stated. Product-specific specifications and quality-control information may vary by compound and batch. Every batch is tested by the manufacturer for purity and concentration as part of routine quality control, using methods such as HPLC and LC-MS. These results are kept in the manufacturer’s internal quality-control records and are not issued as a separate certificate or document.
Research Areas
Sustained GHRH Receptor Pharmacology CJC-1295 with DAC enables sustained GHRHR activation over days rather than minutes, producing a distinct pharmacodynamic profile compared to short-acting GHRH analogues. Research has examined how prolonged GHRHR occupancy affects GH pulse architecture, IGF-1 accumulation, and pituitary somatotroph behavior. This sustained profile is used as an experimental counterpoint to pulsatile GH secretion models in GH axis biology. Drug Affinity Complex Technology Research The DAC modification — maleimido-propionyl-lysine enabling covalent albumin binding — is itself a pharmacokinetic research tool. Studies examining DAC-modified compounds have contributed to understanding of albumin-binding half-life extension strategies, reaction kinetics of maleimide-thiol conjugation in vivo, and the pharmacokinetic implications of albumin as a drug carrier. CJC-1295 with DAC is a well-characterized model compound in this field. GH/IGF-1 Axis Modulation Studies Research protocols using CJC-1295 with DAC have examined downstream GH axis effects including IGF-1 elevation, GH-responsive tissue changes in rodent models, and pituitary feedback regulation. Its use in combination with GHRPs (GHRP-2, GHRP-6, ipamorelin) allows researchers to study synergistic GHRHR and GHS-R1a co-stimulation under conditions of prolonged versus acute GHRH receptor engagement.
Compound Profile
CJC-1295 with DAC (Drug Affinity Complex) is a synthetic 30-amino acid GHRH analogue modified with a Drug Affinity Complex — a maleimido-propionyl group that covalently binds to serum albumin via a Michael addition reaction at Cys³ of albumin. This albumin-binding technology dramatically extends the compound’s plasma half-life from approximately 7 minutes (for native GHRH(1-29)) to an estimated 6-10 days, enabling infrequent administration in research protocols. The extended half-life distinguishes it sharply from CJC-1295 without DAC (also called Modified GRF 1-29), which has a half-life of approximately 30 minutes. In rodent research models, CJC-1295 with DAC produces sustained elevation of circulating GH and IGF-1, with a pharmacokinetic profile more analogous to GH baseline elevation than the pulsatile GH release produced by short-acting GHRH analogues or GHRPs. This distinction has significant implications for research design: pulsatile versus continuous GH elevation engage different downstream signaling patterns and tissue responses. CJC-1295 with DAC is widely used in GH axis research where sustained receptor occupancy at GHRHR rather than pulsatile stimulation is the experimental requirement. Peptides of China supplies CJC-1295 with DAC as a lyophilized powder in sealed vials at 99%+ purity, verified by HPLC and Mass Spectrometry. Every batch is tested by the manufacturer for purity and concentration as part of routine quality control. All products are for laboratory research use only and are not for human consumption.
Profile
Research Areas
GH axis pharmacology, sustained GHRH receptor stimulation, IGF-1 regulation, pituitary function
Available Variants
| Name | Strength | Pack Size | Purity | Availability |
|---|---|---|---|---|
| CJC-1295 With DAC | 2 mg | 10 vials | ≥98% | In Stock |
| CJC-1295 With DAC | 5 mg | 10 vials | ≥98% | Out of Stock |
Specification Highlights
Quality & Testing
Testing method: HPLC / LC-MS . Products are supplied against the specification shown on the applicable product page. The standard catalog purity specification is ≥98% unless otherwise stated. Product-specific specifications and quality-control information may vary by compound and batch. Every batch is tested by the manufacturer for purity and concentration as part of routine quality control, using methods such as HPLC and LC-MS. These results are kept in the manufacturer’s internal quality-control records and are not issued as a separate certificate or document.
Research Areas
Sustained GHRH Receptor Pharmacology CJC-1295 with DAC enables sustained GHRHR activation over days rather than minutes, producing a distinct pharmacodynamic profile compared to short-acting GHRH analogues. Research has examined how prolonged GHRHR occupancy affects GH pulse architecture, IGF-1 accumulation, and pituitary somatotroph behavior. This sustained profile is used as an experimental counterpoint to pulsatile GH secretion models in GH axis biology. Drug Affinity Complex Technology Research The DAC modification — maleimido-propionyl-lysine enabling covalent albumin binding — is itself a pharmacokinetic research tool. Studies examining DAC-modified compounds have contributed to understanding of albumin-binding half-life extension strategies, reaction kinetics of maleimide-thiol conjugation in vivo, and the pharmacokinetic implications of albumin as a drug carrier. CJC-1295 with DAC is a well-characterized model compound in this field. GH/IGF-1 Axis Modulation Studies Research protocols using CJC-1295 with DAC have examined downstream GH axis effects including IGF-1 elevation, GH-responsive tissue changes in rodent models, and pituitary feedback regulation. Its use in combination with GHRPs (GHRP-2, GHRP-6, ipamorelin) allows researchers to study synergistic GHRHR and GHS-R1a co-stimulation under conditions of prolonged versus acute GHRH receptor engagement.